Beilstein J. Nanotechnol.2026,17, 97–121, doi:10.3762/bjnano.17.7
either anti-EGFR immunoliposomes HSPC IM 07 (25 μg/mL) or cetuximab (Erbitux, 25 μg/mL) for 5 min. Each treatment was followed by a 20 min incubation at 37 °C. After incubation, the cells were washed twice, detached with trypsin-EDTA, centrifuged, and resuspended in a live cell buffer containing DAPI (3
PDF
Figure 1:
EE% of formulations. (A) Comparison between liposomes containing R-PE alone and those co-encapsulat...
Beilstein J. Nanotechnol.2022,13, 82–95, doi:10.3762/bjnano.13.6
delivery of an anionic cargo. Besides, a strong intracellular optical signal supports the optically traceable nature of these nanoparticles. SPION@bPEI nanoparticles were further conjugated with Erbitux (Erb), which is an anti-EGFR antibody for targeting EGFR-overexpressing cancer cell lines. SPION@bPEI
selective uptake and hence the targeting ability of Erb-tagged nanoparticles. Altogether, this study proves luminescent, cationic, and small SPION@bPEI nanoparticles as strong candidates for imaging and gene therapy.
Keywords: Erbitux; photoluminescence; polyethyleneimine; polyinosinic–polycytidylic acid
therapeutic dose. Next, SPION@bPEI were conjugated with Erbitux (Erb), which is an anti-EGFR antibody for targeting EGFR-overexpressing cancer cell lines. Finally, SPION@bPEI-Erb nanoparticles were used for the targeted delivery of a GFP plasmid, whose transfection can be confirmed with the luminescence of
PDF
Figure 1:
a) TEM image of SPION@bPEI. b) AFM micrograph image of SPION@bPEI (magnetic mode). c) X-ray diffrac...